Chi­na's mar­ket reg­u­la­tor fines, con­fis­cates rev­enue from phar­mas for mo­nop­o­liz­ing APIs for ep­i­neph­rine

Chi­na’s mar­ket reg­u­la­tor, the State Ad­min­is­tra­tion for Mar­ket Reg­u­la­tion, an­nounced on Sun­day that it fined and con­fis­cat­ed rev­enue from two phar­ma com­pa­nies for what it called a mo­nop­o­lis­tic deal.

Grand Phar­ma­ceu­ti­cal was fined $19.68 mil­lion (139.3 mil­lion yuan) and the reg­u­la­tor con­fis­cat­ed $21 mil­lion (149 mil­lion yuan) of what it called “il­le­gal rev­enue” for en­ter­ing in­to a mo­nop­oly with Wuhan Heal­care Phar­ma­ceu­ti­cals over two drugs and their ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs): nor­ep­i­neph­rine bitar­trate and ep­i­neph­rine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.